Tucker UNLEASHES on Designer Baby CEO

Tucker Carlson confronts biotech CEO Kian Sadeghi over embryo selection technology that lets parents pick babies for IQ and height, warning it revives Nazi-era eugenics and defies God’s design for life.

Story Highlights

Carlson debates Nucleus Genomics CEO on IVF genetic testing for diseases like cancer and traits like intelligence, allowing “customization” without DNA edits.
Discussion exposes eugenics risks, embryo souls, and “playing God,” drawing Nazi history and India’s sex-selection ban as cautionary tales.
Nucleus, backed by $32M from tech investors, empowers parental choice but sparks fears of designer babies widening class divides.
Episode, released April 14, 2026, amplifies bioethics clash amid unregulated U.S. trait selection, contrasting with global restrictions.

Debate Ignites Over Embryo Selection

Tucker Carlson hosted Kian Sadeghi, founder of Nucleus Genomics, on The Tucker Carlson Show released April 14, 2026. Sadeghi explained his company’s IVF service, which screens embryos for disease risks including cancers, Alzheimer’s, and diabetes, plus traits like IQ and height. Parents select preferred embryos without altering DNA through editing. Carlson pressed Sadeghi on moral boundaries at timestamps like 33:38 on life’s right and 37:44 on embryo souls. The exchange highlighted tensions between technology and natural order. Conservatives view this as eroding divine creation principles central to American founding values of limited human hubris.

Historical Echoes of Eugenics

Carlson invoked Nazi eugenics programs from the 1930s-1940s, which sterilized “undesirables,” paralleling modern trait selection at 49:21 in the episode. Sadeghi differentiated Nucleus as informational, not coercive, emphasizing parental virtue over genetic determinism. He cited India’s 1994 sex-selective abortion ban, which Carlson used to illustrate societal harms like skewed sex ratios. Precedents include the 2018 CRISPR babies scandal and U.K. restrictions on trait selection. U.S. lacks federal bans, fueling concerns that unregulated biotech invites elite-driven redesign of humanity, betraying equal opportunity ideals.

Stakeholders and Power Dynamics

Sadeghi, a Thiel Fellow who founded Nucleus in 2021, secured $32 million from Founders Fund, Seven Seven Six, and Samsung Next to disrupt the $20 billion genomics market. He portrays selection as empowerment for IVF parents, limiting genetics to physical traits while attributing virtue to divine sources. Carlson, wielding a massive audience, critiques this as transhumanist overreach violating life’s sacred origins. Disability advocates worry over Down syndrome screening ethics, and religious communities decry soul negation. Investors prioritize profits, while public opinion, amplified by Carlson, may drive policy amid GOP control.

Societal Risks and Broader Impacts

Short-term, the episode garnered 43,000 YouTube views quickly, boosting Nucleus visibility and bioethics discourse. Long-term, normalizing polygenic selection risks “designer babies” accessible mainly to the wealthy, reducing human diversity and exacerbating divides between haves and have-nots. IVF accounts for about 2% of U.S. births, with firms like Genomic Prediction pioneering trait screening since 2019. Social fears mirror India’s imbalances; politically, it pressures regulation in a Trump-era Congress wary of deep state tech overreach. Both conservatives and liberals share distrust of elite manipulations undermining the American Dream.

Tucker Debates Biotech CEO on Baby Customization, Eugenics, and God’s Existencehttps://t.co/PxsOo5p6Ry

— Richard L. Craven (@RichardLCraven_) April 15, 2026

Philosophical Clash on Life’s Origins

At 1:02:14, Carlson accused the practice of “playing God,” asserting humans should not tamper with life’s formula. Sadeghi countered with a Sufi-inspired view of God as an experiential “ocean” beyond logic, separating biological traits from spiritual essence. Bioethicists warn of eugenics slippery slopes, while geneticists highlight disease prevention. This split echoes frustrations across political lines: government and corporate elites prioritize innovation over foundational principles like natural law and individual dignity. The debate underscores calls for ethical limits protecting vulnerable citizens from biotech excesses.